JCEM:在亚洲人群中使用HbA1c诊断糖尿病:一项基于多种族亚洲人群的HbA1c与视网膜病变的相关性研究

2014-11-08 MedSci MedSci原创

研究背景: 近来国际上已经把糖化血红蛋白(HbA1c)大于6.5%(47.5 mmol/mol)纳入糖尿病的诊断标准,但这个诊断标准在亚洲人群中是否使用仍然不明。 研究目的: 探究亚洲人群中HbA1c与糖尿病特异性中度视网膜病变之间的相关性。 研究设计及受试者: 4个独立人群:一个人群是来自一项在2004-2011年间开展的横断面研究(≥25 岁的成年人,n=131

研究背景:

近来国际上已经把糖化血红蛋白(HbA1c)大于6.5%47.5 mmol/mol)纳入糖尿病的诊断标准,但这个诊断标准在亚洲人群中是否使用仍然不明。

研究目的:

探究亚洲人群中HbA1c糖尿病特异性中度视网膜病变之间的相关性。

研究设计及受试者:

4个独立人群:一个人群是来自一项在2004-2011年间开展的横断面研究(≥25 岁的成年人,n=13170),另三个主要亚洲人种来自中国(n=5834),马拉西亚(n=3596)和印度(n=3740)。

主要终点事件:

使用数字视网膜照相评估受试者的视网膜情况,并把早期治疗糖尿病视网膜病变研究(ETDRS)的测量值>43定义为中度视网膜病变。对各种族人群在不同HbA1c切点水平比较了中度视网膜病变检测相关的敏感性、特异性、阳性预测值(PPV)和阴性预测值(NPV)以及为受试者操作特性曲线的曲线下面积等结果。

研究结果:

印度人及马来人的HbA1c水平高于中国人(p<0.001)。在所有种族人群中,HbA1c<6.5%受试者中度视网膜病变的发生率均<1%。而在HbA1c ≥6.5%的受试者中,与印度人及马来人比较,中国人群检测出中度视网膜病变的敏感性较低(75.8% vs. 86.0%, 85.3%),但特异性更高(89.7% vs. 71.9%, 76.3%),另外PPVNPV在中国人、印度人和马来人中相近(10.5%, 12.3%, 12.4%; 99.6%, 99.1%, 99.2%),曲线下面积也相似(0.861, 0.851 0.853)。

研究结论:

我们的研究结果支持在亚洲人群中使用HbA1c作为糖尿病诊断标准。虽然HbA1c与视网膜病变的相关性在不同人种之间存在部分差异,但经三个主要亚洲人种人群证实把6.5%作为切点是合理的。

原文出处:

Charumathi Sabanayagam, Eric YH Khoo, Weng Kit Lye, M Kamran Ikram, Ecosse L Lamoureux, Ching Yu Cheng, Maudrene LS Tan, Agus Salim, Jeannette JM Lee, Su-Chi Lim, Subramaniam Tavintharan, Ah-Chuan Thai, Derrick Heng, Stefan Ma, E Shyong Tai, and Tien Y Wong. Diagnosis of Diabetes Mellitus using HbA1c in Asians: Relationship between HbA1c and Retinopathy in a Multi-Ethnic Asian Population. JCEM, Nov 06, 2014.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2015895, encodeId=081420158959c, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Oct 10 09:32:00 CST 2015, time=2015-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062870, encodeId=e77a20628e0ce, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Thu Sep 17 02:32:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777489, encodeId=00a01e77489e5, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sat Dec 20 22:32:00 CST 2014, time=2014-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26339, encodeId=4fb326339ad, content=好好学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Mon Jun 08 14:11:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20492, encodeId=48ee2049237, content=控制好糖尿病可能提高肝硬化患者的预后。, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:02:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837155, encodeId=b261183e1558e, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Jun 22 15:32:00 CST 2015, time=2015-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269801, encodeId=bde61269801b2, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon Nov 10 03:32:00 CST 2014, time=2014-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413860, encodeId=e3161413860b4, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Mon Nov 10 03:32:00 CST 2014, time=2014-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619857, encodeId=5ecf161985e2a, content=<a href='/topic/show?id=1f652426921' target=_blank style='color:#2F92EE;'>#亚洲人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24269, encryptionId=1f652426921, topicName=亚洲人群)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon Nov 10 03:32:00 CST 2014, time=2014-11-10, status=1, ipAttribution=)]
    2015-10-10 Smile2680
  2. [GetPortalCommentsPageByObjectIdResponse(id=2015895, encodeId=081420158959c, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Oct 10 09:32:00 CST 2015, time=2015-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062870, encodeId=e77a20628e0ce, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Thu Sep 17 02:32:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777489, encodeId=00a01e77489e5, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sat Dec 20 22:32:00 CST 2014, time=2014-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26339, encodeId=4fb326339ad, content=好好学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Mon Jun 08 14:11:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20492, encodeId=48ee2049237, content=控制好糖尿病可能提高肝硬化患者的预后。, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:02:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837155, encodeId=b261183e1558e, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Jun 22 15:32:00 CST 2015, time=2015-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269801, encodeId=bde61269801b2, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon Nov 10 03:32:00 CST 2014, time=2014-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413860, encodeId=e3161413860b4, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Mon Nov 10 03:32:00 CST 2014, time=2014-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619857, encodeId=5ecf161985e2a, content=<a href='/topic/show?id=1f652426921' target=_blank style='color:#2F92EE;'>#亚洲人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24269, encryptionId=1f652426921, topicName=亚洲人群)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon Nov 10 03:32:00 CST 2014, time=2014-11-10, status=1, ipAttribution=)]
    2015-09-17 achengzhao
  3. [GetPortalCommentsPageByObjectIdResponse(id=2015895, encodeId=081420158959c, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Oct 10 09:32:00 CST 2015, time=2015-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062870, encodeId=e77a20628e0ce, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Thu Sep 17 02:32:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777489, encodeId=00a01e77489e5, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sat Dec 20 22:32:00 CST 2014, time=2014-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26339, encodeId=4fb326339ad, content=好好学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Mon Jun 08 14:11:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20492, encodeId=48ee2049237, content=控制好糖尿病可能提高肝硬化患者的预后。, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:02:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837155, encodeId=b261183e1558e, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Jun 22 15:32:00 CST 2015, time=2015-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269801, encodeId=bde61269801b2, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon Nov 10 03:32:00 CST 2014, time=2014-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413860, encodeId=e3161413860b4, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Mon Nov 10 03:32:00 CST 2014, time=2014-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619857, encodeId=5ecf161985e2a, content=<a href='/topic/show?id=1f652426921' target=_blank style='color:#2F92EE;'>#亚洲人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24269, encryptionId=1f652426921, topicName=亚洲人群)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon Nov 10 03:32:00 CST 2014, time=2014-11-10, status=1, ipAttribution=)]
    2014-12-20 smallant2015
  4. [GetPortalCommentsPageByObjectIdResponse(id=2015895, encodeId=081420158959c, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Oct 10 09:32:00 CST 2015, time=2015-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062870, encodeId=e77a20628e0ce, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Thu Sep 17 02:32:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777489, encodeId=00a01e77489e5, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sat Dec 20 22:32:00 CST 2014, time=2014-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26339, encodeId=4fb326339ad, content=好好学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Mon Jun 08 14:11:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20492, encodeId=48ee2049237, content=控制好糖尿病可能提高肝硬化患者的预后。, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:02:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837155, encodeId=b261183e1558e, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Jun 22 15:32:00 CST 2015, time=2015-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269801, encodeId=bde61269801b2, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon Nov 10 03:32:00 CST 2014, time=2014-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413860, encodeId=e3161413860b4, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Mon Nov 10 03:32:00 CST 2014, time=2014-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619857, encodeId=5ecf161985e2a, content=<a href='/topic/show?id=1f652426921' target=_blank style='color:#2F92EE;'>#亚洲人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24269, encryptionId=1f652426921, topicName=亚洲人群)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon Nov 10 03:32:00 CST 2014, time=2014-11-10, status=1, ipAttribution=)]
    2015-06-08 ljjj1053

    好好学习学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2015895, encodeId=081420158959c, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Oct 10 09:32:00 CST 2015, time=2015-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062870, encodeId=e77a20628e0ce, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Thu Sep 17 02:32:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777489, encodeId=00a01e77489e5, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sat Dec 20 22:32:00 CST 2014, time=2014-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26339, encodeId=4fb326339ad, content=好好学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Mon Jun 08 14:11:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20492, encodeId=48ee2049237, content=控制好糖尿病可能提高肝硬化患者的预后。, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:02:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837155, encodeId=b261183e1558e, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Jun 22 15:32:00 CST 2015, time=2015-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269801, encodeId=bde61269801b2, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon Nov 10 03:32:00 CST 2014, time=2014-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413860, encodeId=e3161413860b4, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Mon Nov 10 03:32:00 CST 2014, time=2014-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619857, encodeId=5ecf161985e2a, content=<a href='/topic/show?id=1f652426921' target=_blank style='color:#2F92EE;'>#亚洲人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24269, encryptionId=1f652426921, topicName=亚洲人群)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon Nov 10 03:32:00 CST 2014, time=2014-11-10, status=1, ipAttribution=)]
    2015-04-11 x35042875

    控制好糖尿病可能提高肝硬化患者的预后。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2015895, encodeId=081420158959c, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Oct 10 09:32:00 CST 2015, time=2015-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062870, encodeId=e77a20628e0ce, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Thu Sep 17 02:32:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777489, encodeId=00a01e77489e5, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sat Dec 20 22:32:00 CST 2014, time=2014-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26339, encodeId=4fb326339ad, content=好好学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Mon Jun 08 14:11:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20492, encodeId=48ee2049237, content=控制好糖尿病可能提高肝硬化患者的预后。, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:02:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837155, encodeId=b261183e1558e, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Jun 22 15:32:00 CST 2015, time=2015-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269801, encodeId=bde61269801b2, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon Nov 10 03:32:00 CST 2014, time=2014-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413860, encodeId=e3161413860b4, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Mon Nov 10 03:32:00 CST 2014, time=2014-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619857, encodeId=5ecf161985e2a, content=<a href='/topic/show?id=1f652426921' target=_blank style='color:#2F92EE;'>#亚洲人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24269, encryptionId=1f652426921, topicName=亚洲人群)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon Nov 10 03:32:00 CST 2014, time=2014-11-10, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2015895, encodeId=081420158959c, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Oct 10 09:32:00 CST 2015, time=2015-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062870, encodeId=e77a20628e0ce, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Thu Sep 17 02:32:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777489, encodeId=00a01e77489e5, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sat Dec 20 22:32:00 CST 2014, time=2014-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26339, encodeId=4fb326339ad, content=好好学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Mon Jun 08 14:11:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20492, encodeId=48ee2049237, content=控制好糖尿病可能提高肝硬化患者的预后。, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:02:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837155, encodeId=b261183e1558e, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Jun 22 15:32:00 CST 2015, time=2015-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269801, encodeId=bde61269801b2, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon Nov 10 03:32:00 CST 2014, time=2014-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413860, encodeId=e3161413860b4, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Mon Nov 10 03:32:00 CST 2014, time=2014-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619857, encodeId=5ecf161985e2a, content=<a href='/topic/show?id=1f652426921' target=_blank style='color:#2F92EE;'>#亚洲人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24269, encryptionId=1f652426921, topicName=亚洲人群)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon Nov 10 03:32:00 CST 2014, time=2014-11-10, status=1, ipAttribution=)]
    2014-11-10 zutt
  8. [GetPortalCommentsPageByObjectIdResponse(id=2015895, encodeId=081420158959c, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Oct 10 09:32:00 CST 2015, time=2015-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062870, encodeId=e77a20628e0ce, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Thu Sep 17 02:32:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777489, encodeId=00a01e77489e5, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sat Dec 20 22:32:00 CST 2014, time=2014-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26339, encodeId=4fb326339ad, content=好好学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Mon Jun 08 14:11:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20492, encodeId=48ee2049237, content=控制好糖尿病可能提高肝硬化患者的预后。, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:02:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837155, encodeId=b261183e1558e, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Jun 22 15:32:00 CST 2015, time=2015-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269801, encodeId=bde61269801b2, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon Nov 10 03:32:00 CST 2014, time=2014-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413860, encodeId=e3161413860b4, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Mon Nov 10 03:32:00 CST 2014, time=2014-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619857, encodeId=5ecf161985e2a, content=<a href='/topic/show?id=1f652426921' target=_blank style='color:#2F92EE;'>#亚洲人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24269, encryptionId=1f652426921, topicName=亚洲人群)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon Nov 10 03:32:00 CST 2014, time=2014-11-10, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=2015895, encodeId=081420158959c, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Oct 10 09:32:00 CST 2015, time=2015-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062870, encodeId=e77a20628e0ce, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Thu Sep 17 02:32:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777489, encodeId=00a01e77489e5, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sat Dec 20 22:32:00 CST 2014, time=2014-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26339, encodeId=4fb326339ad, content=好好学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Mon Jun 08 14:11:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20492, encodeId=48ee2049237, content=控制好糖尿病可能提高肝硬化患者的预后。, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:02:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837155, encodeId=b261183e1558e, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Jun 22 15:32:00 CST 2015, time=2015-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269801, encodeId=bde61269801b2, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon Nov 10 03:32:00 CST 2014, time=2014-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413860, encodeId=e3161413860b4, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Mon Nov 10 03:32:00 CST 2014, time=2014-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619857, encodeId=5ecf161985e2a, content=<a href='/topic/show?id=1f652426921' target=_blank style='color:#2F92EE;'>#亚洲人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24269, encryptionId=1f652426921, topicName=亚洲人群)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon Nov 10 03:32:00 CST 2014, time=2014-11-10, status=1, ipAttribution=)]

相关资讯

Diabetes Care:糖尿病与认知能力间存因果关系

近日,刊登在国际杂志Diabetes Care上的一篇研究论文中,来自以色列特拉维夫大学(Tel Aviv University)等处的研究人员评估了年轻男性认知功能和其患糖尿病风险之间的内在关联。 近些年来,很多研究都发现糖尿病是加速个体认知功能下降、患痴呆症的重要风险因子,然而个体认知功能和糖尿病发病之间的关联却并不清楚,因此本文中研究者对这两者之间的关系进行了深入的研究剖析。 文章中

Lancet Diab & Endo:减重术降低2型糖尿病的发生率

目前,许多肥胖症患者接受减重术,但是尚不清楚减重术是否影响糖尿病的进程,近期,研究人员在大规模的肥胖症患者人群中评估了减重手术对2型糖尿病的影响。 研究方法: 基于英国家庭医疗数据库,研究人员针对成年肥胖人群(年龄20-100岁,BMI≥30 kg/m2)进行配对横断面研究。研究人员招募2167名自2002年1月1日至2014年4月30日期间接受减重术的肥胖患者,并根据BMI、年龄、性别、糖

Diabetes Care:低脂联素水平或增加心肌梗塞病人2型糖尿病的患病风险

近日,来自哥本哈根根措夫特大学医院的研究人员通过研究表明,机体脂联素水平较低或和心肌梗塞病人患2型糖尿病风险增加相关,相关研究刊登于近日的国际杂志Diabetes Care上。 文章中,研究者Lindberg表示,急性心肌梗塞(MI)病人患2型糖尿病的风险往往会增加,而脂联素是脂肪细胞分泌的一种胰岛素致敏性激素,其可以直接抑制肝糖异生作用,从而刺激脂肪酸的氧化及骨骼肌中葡萄糖的摄取及胰岛素的

J Clin Invest:胆汁酸能够治疗糖尿病

近日,来自瑞士洛桑联邦理工大学的科学家与来自意大利和荷兰的研究人员共同发现:胆汁酸能够激活一个鲜为人知的受体来克服脂肪细胞对胰岛素敏感度的丧失,这种机制或能用于发展一种新型药物来治疗2型糖尿病。本研究成果题为“TGR5 reduces macrophage migration through mTOR-induced C/EBPβ differential translation”于近日发表在th

滕卫平:临床科研选题出发,思考糖尿病研究

(全体大会Ⅰ,时间:11月6日09:50~10:20,地点:世纪大会堂) 滕卫平 课题是研究方向的基础,课题的积累形成研究方向。首先,课题要具有创新性。创新就是回答前人没有回答的问题,解决前人没有解决的问题。医学科研的特殊性在于生物学的多样性。其二,题目要有科学意义。特别是在我国,按照“有所为,有所不为”的原则,一定要强调题目的,强调对于社会发展、防病治病的作用,而不能凭借

JCEM:骨小梁评分可以预测糖尿病患者骨骼退化情况

研究背景: 骨小梁评分(TBS)作为一个新的质地指数,对双能X线骨密度测量法(DXA)图像上腰椎灰度水平的像素变化进行评估,它与骨骼微结构的相关关系不依赖于骨密度(BMD)值的高低。 研究目标: 我们为糖尿病患者测定腰椎TBS,并以此预测骨骼退化的情况。 研究设计及实施: 研究对象来自一项在2009-2010年间进行的基于人群的前瞻性队列研究,我们收集了横断面数据进行